Fig. 1

Prediction of SV-derived neoantigens across 2528 tumors. a Overview of the NeoSV workflow. b The number of SV-derived neoantigens per patient across 30 cancer types. Within each cancer type, patients are sorted by SV-derived neoantigen load. Red bars indicate median values. c–e The numbers of SV-derived neoantigens per patient categorized by the functional impact on proteins (c), SV type (d), and genomic location relative to genes (e). Medians ± s.e.m of the number of SV-derived neoantigens are plotted. h2h inversion, head-to-head inversion; t2t inversion, tail-to-tail inversion